Follistatin FAQs
← back to Follistatin
5 questions
FAQs
- What is follistatin, and how does it influence hair follicle growth and regeneration? Follistatin blocks activin and related growth-inhibiting proteins, which in laboratory and animal work is described as keeping hair follicles in their growth phase; the only verifiable human evidence is a single small 2011 phase 1 injection trial, so follistatin remains experimental and is not an approved hair-loss treatment.
- Can follistatin be applied topically, or is it only effective through injections or systemic use? Follistatin is not effective when applied topically and requires injections or systemic use.
- How does follistatin compare to finasteride or dutasteride for treating androgenic alopecia? Finasteride and dutasteride are prescription drugs with large controlled trials showing they lower DHT and slow androgenic hair loss, at the cost of documented hormonal side effects; follistatin targets a different, regenerative pathway but has only one small phase 1 human trial behind it, so it is experimental with unknown safety rather than a comparable alternative.
- Are there any clinical studies supporting follistatin as a hair loss treatment? There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.
- Is follistatin safe for use in women or transgender individuals undergoing hormone therapy? No study has tested follistatin in women or transgender people on hormone therapy, and it has no approved human use or established dose; the one relevant signal, from a 2023 randomized study in adolescents with PCOS, links higher follistatin to less favourable metabolic markers, so the published evidence does not support using it in this group.